中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2014年
33期
27-28,32
,共3页
倍他乐克%慢性心衰%治疗效果%观察
倍他樂剋%慢性心衰%治療效果%觀察
배타악극%만성심쇠%치료효과%관찰
Metoprolol%Chronic heart failure%Treatment effect%Observation
目的：就倍他乐克对慢性心衰的治疗效果进行分析。方法选择该院2005年11月—2013年11月所收治的100例慢性心衰患者，基于随机数字法将患者分为两组，分别是治疗组50例和对照组50例，对照组予以营养心肌药物、扩血管、休息、强心利尿、吸氧等一系列常规治疗，而治疗组在对照组基础上使用倍他乐克。结果对照组有效率为80%；治疗组有效率为94%，两组有效率差异有统计学意义（P＜0.05）。治疗组心力衰竭指标的改善程度明显要优于对照组，差异有统计学意义（P＜0.05）。结论慢性心衰患者加用倍他乐克治疗，能够较好地提高临床疗效，改善心力衰竭指标，安全可靠，值得推广应用。
目的：就倍他樂剋對慢性心衰的治療效果進行分析。方法選擇該院2005年11月—2013年11月所收治的100例慢性心衰患者，基于隨機數字法將患者分為兩組，分彆是治療組50例和對照組50例，對照組予以營養心肌藥物、擴血管、休息、彊心利尿、吸氧等一繫列常規治療，而治療組在對照組基礎上使用倍他樂剋。結果對照組有效率為80%；治療組有效率為94%，兩組有效率差異有統計學意義（P＜0.05）。治療組心力衰竭指標的改善程度明顯要優于對照組，差異有統計學意義（P＜0.05）。結論慢性心衰患者加用倍他樂剋治療，能夠較好地提高臨床療效，改善心力衰竭指標，安全可靠，值得推廣應用。
목적：취배타악극대만성심쇠적치료효과진행분석。방법선택해원2005년11월—2013년11월소수치적100례만성심쇠환자，기우수궤수자법장환자분위량조，분별시치료조50례화대조조50례，대조조여이영양심기약물、확혈관、휴식、강심이뇨、흡양등일계렬상규치료，이치료조재대조조기출상사용배타악극。결과대조조유효솔위80%；치료조유효솔위94%，량조유효솔차이유통계학의의（P＜0.05）。치료조심력쇠갈지표적개선정도명현요우우대조조，차이유통계학의의（P＜0.05）。결론만성심쇠환자가용배타악극치료，능구교호지제고림상료효，개선심력쇠갈지표，안전가고，치득추엄응용。
Objective To analyze the treatment effect of metoprolol on chronic heart failure. Methods 100 patients with chronic heart failure admitted in our hospital from November 2005 to November 2013 were selected and divided into two groups according to the random number method, the treatment group (50 cases) and control group (50 cases). The control group was given a series of conventional treatment such as drugs for nourishing the cardiac muscle, vasodilator, rest, cardiac diuretic, oxygen inhalation and so on. And the treatment group was given metoprolol based on the treatment given to the control group. Results The effective rate of the control group was 80%, and that of the treatment group was 94%, the difference between the two groups was statistically signif-icant (P<0.05). The improvement in heart failure indexes of the treatment group was much better than that of the control group with statistical significance (P<0.05). Conclusion For patients with chronic heart failure, metoprolol can better improve the clinical effi-cacy and the heart failure indicators, it is safe and reliable, and is worthy of application and promotion.
